Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37529
Title: | Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma | Authors: | Devos , Timothy Van Thillo, Quentin Compernolle, Veerle Najdovski, Tome Romano, Marta Dauby, Nicolas Jadot, Laurent Leys, Mathias Maillart, Evelyne Loof, Sarah Seyler , Lucie Moonen , Martial Moutschen, Michel Van Regenmortel, Niels Arien, Kevin K. Barbezange, Cyril Betrains, Albrecht Garigliany, Mutien Engelen, Matthias M. Gyselinck, Iwein Maes, Piet Schauwvlieghe, Alexander Liesenborghs, Laurens Belmans, Ann Verhamme, Peter Meyfroidt, Geert |
Issue Date: | 2022 | Publisher: | EUROPEAN RESPIRATORY SOC JOURNALS LTD | Source: | EUROPEAN RESPIRATORY JOURNAL, 59 (2) (Art N° 2101724) | Abstract: | Background Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness. Methods In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT50)) >= 1/320 was the product of choice for the study. Results Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806-906) mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT50) >= 1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59-1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%). Conclusions Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality. | Notes: | Meyfroidt, G (corresponding author), Katholieke Univ Leuven, Dept Intens Care Med, Dept Cellular & Mol Med, Lab Intens Care Med,Univ Hosp Leuven, Leuven, Belgium. geert.meyfroidt@uzleuven.be |
Keywords: | Adult;Antibodies, Neutralizing;Antibodies, Viral;Hospitalization;Humans;Prospective Studies;Treatment Outcome;COVID-19;Immunization, Passive | Document URI: | http://hdl.handle.net/1942/37529 | ISSN: | 0903-1936 | e-ISSN: | 1399-3003 | DOI: | 10.1183/13993003.01724-2021 | ISI #: | WOS:000798166900002 | Rights: | ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org This article has an editorial commentary: https://doi.org/10.1183/ 13993003.02076-2021 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients_ DAWn-plasma.pdf | Published version | 740.08 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.